Why Cardiol Therapeutics Inc.’s (CRDL) Stock Is Down 6.37%
As of Friday, November 13, Cardiol Therapeutics Inc.’s CRDL share price has dipped by 6.37%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
Michael Rose
Rosalio Madrigal
Jenna Brashear
Rosalio Madrigal
| Share Statistics | CRDL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $113.5 | $433.9 | 24% |
|
| Shares Out (Mil) | 83.1 | 46.5 | 58% |
|
| Institutional Ownership | 82.6% | 82.2% | 50% |
|
| Float (Mil) | 97.7 | 47.7 | 59% |
|
| Beta | na | 0.74 | na |
|
| Avg Daily Volume (000s) | 498 | 345 | 56% |
|
| Price Change (52-week) |
(3.9%) | 52.0% | 47% |
|
| Growth | CRDL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.4% | na |
|
| Net Income (5yr) | (8.8%) | (1.6%) | 30% |
|
| EPS (5yr) | 12.2% | 15.1% | 51 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (19.7%) | (15.1%) | 34% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 3 | 4 | |
| Current EPS | ($0.068) | ($0.222) | ($0.230) | |
| Month Ago EPS | ($0.058) | ($0.222) | ($0.228) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.063) | ($0.227) | ($0.212) | |
| Year/Year Chg | (15.0%) | (21.8%) | (81.3%) | |
| Financials | CRDL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $289 | na |
|
| Net Income (TTM) (Mil) | ($26) | ($11) | 21% |
|
| EPS (TTM) | ($0.240) | ($0.600) | 32% |
|
| Operating Cash Flow (TTM) (Mil) | ($15) | ($7) | 17% |
|
| Net Cash Flow (TTM) (Mil) | $13 | $1 | 60% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 0% |
|
| Enterprise Value (Q1) (Mil) | $100 | $331 | 22% |
|
| Valuation | CRDL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 6.12 | 2.05 | 85% |
|
| P/E | na | 24.3 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | CRDL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.5% | na |
|
| Net Margin | na | 3.9% | na |
|
| ROA | (162.5%) | (23.3%) | 2% |
|
| ROE | (200.5%) | (21.8%) | 4% |
|
| Liabilities to Assets | 16.1% | 31.2% | 10% |
|
| F-Score | 4 | 3 | 33% |
|
Cardiol Therapeutics Inc. did not pass any screens on 11/16/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors